SUMMARY
STAT3
, an essential transcription factor with pleiotropic functions, plays critical roles in the pathogenesis of autoimmunity. Despite recent data linking STAT3 with inflammatory bowel disease, exactly how it contributes to chronic intestinal inflammation is not known. Using a T cell transfer model of colitis, we found that STAT3 expression in T cells was essential for the induction of both colitis and systemic inflammation. STAT3 was critical in modulating the balance of T helper 17 (Th17) and regulatory T (Treg) cells, as well as in promoting CD4 + T cell proliferation. We used chromatin immunoprecipitation and massive parallel sequencing (ChIP-Seq) to define the genome-wide targets of STAT3 in CD4 + T cells. We found that STAT3 bound to multiple genes involved in Th17 cell differentiation, cell activation, proliferation, and survival, regulating both expression and epigenetic modifications. Thus, STAT3 orchestrates multiple critical aspects of T cell function in inflammation and homeostasis.
INTRODUCTION
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that serves critical functions in development, cell growth, and homeostasis in a variety of tissues (Hirano et al., 2000; Levy and Lee, 2002) . Germline deletion in mice leads to embryonic lethality most likely due to STAT3's essential functions in mediating leukemia inhibitory factor (LIF) signaling as well as other gp130 family cytokines (Takeda et al., 1997) . Conversely, inappropriate activation of STAT3 is associated with malignant transformation and the pathogenesis of various types of cancers (Haura et al., 2005) . In hematopoietic cells, STAT3 is an important negative regulator of the granulocyte colony-stimulating factor (G-CSF) pathway and granulopoiesis and is essential for the actions of interleukin-10 (IL-10) (Murray, 2006) . Surprisingly, despite its critical roles in other tissues, conditional deletion of STAT3 in T cells revealed no overt developmental deficits 
. Even though Stat3
À/À T cells were reported to have reduced IL-6-dependent proliferation in vitro, mice lacking Stat3 in their T cells had normal thymic development and peripheral T cell compartments (Akaishi et al., 1998) . After activation, CD4 + T cells can differentiate into specialized subsets in the periphery, which are required for proper immune regulation and host defense. In addition to previously recognized T helper 1 (Th1) and Th2 fates, naive CD4 + T cells can also differentiate into Th17 and regulatory T (Treg) cells; the balance of Th17 and Treg cells is now considered to be critical for host immunity and the preservation of tolerance (Bettelli et al., 2008; Stockinger and Veldhoen, 2007; Weaver et al., 2007; Yang et al., 2008a) . Cytokines that activate STAT3, including IL-6, IL-21 and IL-23, are important drivers of Th17 cell differentiation and promote immunity against extracellular bacteria and fungi (Aggarwal et al., 2003; Bettelli et al., 2006; Nishihara et al., 2007; Nurieva et al., 2007) . Accordingly, we and others have shown that STAT3 plays a critical role in the differentiation of CD4 + T cells into Th17 cells (Chen et al., 2006; Laurence et al., 2007; Mathur et al., 2007; Wei et al., 2007; Yang et al., 2007) . Patients with Job's or Hyper IgE Syndrome (HIES) have dominant-negative mutations of STAT3 and are deficient in Th17 cells, underscoring the close link between STAT3 and Th17 cells (Holland et al., 2007; Ma et al., 2008; Milner et al., 2008; Minegishi et al., 2007) . The human inflammatory bowel diseases (IBDs) comprise a wide spectrum of disorders, characterized by chronic inflammation of the intestine, and several lines of evidence point to the potential involvement of STAT3 and Th17 cells in disease pathogenesis. Genome-wide association studies have identified polymorphisms in the IL23R, JAK2, and STAT3 genes associated with increased susceptibility to IBDs (Barrett et al., 2008; Duerr et al., 2006) . Furthermore, phosphorylated STAT3 and IL-17 are features of the inflammatory response in IBDs and colitis models, but the requirement for STAT3 in models of colitis, particularly with respect to T cell-dependent pathology, has not been explored (Fujino et al., 2003; Suzuki et al., 2001) . Moreover, despite the link between STAT3 and models of Th17 cell-mediated diseases, our understanding of how STAT3 contributes to immunoregulation in terms of its gene targets is remarkably limited (Harris et al., 2007; Liu et al., 2008) .
Using a T cell-transfer model of colitis, we found that STAT3 is essential for driving both colitis and systemic inflammation not only by modulating Th17 and Treg cell differentiation but also by allowing T cell homeostatic expansion. To comprehensively delineate STAT3 targets in T cells, we employed chromatin immunoprecipitation followed by massive parallel sequencing (ChIP-Seq). We found that STAT3 binds most of the genes shown to promote Th17 cell fate determination, as well as many genes involved in T cell survival and proliferation. Thus, STAT3 has diverse, yet critical functions in the differentiation, proliferation, and survival of T cells in the setting of chronic inflammatory disease. In addition to localized colonic pathology, transfer of naive T cells into lymphopenic hosts induces systemic inflammation manifested by splenic enlargement and elevated serum levels of inflammatory cytokines and chemokines. Accordingly, we found that Rag2 À/À mice reconstituted with control T cells developed splenomegaly, associated with the presence of IL-6, IL12p70, MCP-1, and TNF-a in the serum ( Figures 1D and 1E ). In contrast, mice reconstituted with Stat3 À/À T cells had normalsized spleens and significantly lower serum concentrations of inflammatory cytokines, whereas concentrations of IL-10 were similar to controls ( Figure 1E ). STAT3 was therefore critical for driving not only the tissue-specific pathology in the colon but also systemic inflammatory responses. Figure 2C ). On the contrary, a significantly higher proportion of IFN-g + CD4 + T cells were present in the spleens of mice that received Stat3 À/À T cells; however, the absolute number of IFN-g + T cells in the tissues was not significantly different between the two groups ( Figure S1B ). Thus, our data support the conclusion that STAT3 is necessary for IL-17A but not IFN-g production by CD4 + T cells in this model of colitis.
RESULTS

STAT3 Is Required for T Cell-Dependent Colitis
STAT3 Is Required for Th17 Cell Differentiation in Colitis
STAT3 Inhibits Regulatory T Cell Conversion
Treg cells are a specialized population of CD4 + T cells that express the forkhead/winged-helix protein Foxp3, and they dampen inflammatory responses and prevent autoimmunity (Josefowicz and Rudensky, 2009 ). In addition to eliciting inflammation, both IL-23 and IL-6 inhibit Treg cell differentiation and can thereby contribute to immune pathology (Izcue et al., 2008; Korn et al., 2008 Figure S2A ). Similar proportions of IL-10 + T cells were also present in both groups of mice ( Figure S2B ). Thus, STAT3 appeared to inhibit the conversion of naive T cells into Foxp3 + cells in vivo in the inflammatory setting. In addition to the paucity of IL-17-producing cells, these data provide another explanation for why mice reconstituted with Stat3 À/À T cells did not develop colitis or systemic disease.
STAT3 Directly Regulates Most Genes Involved in Th17
Cell Differentiation Our data point to nonredundant, essential roles for STAT3 in regulating the balance between Th17 and Treg cell differentiation in vivo. To better define how STAT3 contributes to this decision, we identified STAT3 targets genome-wide using transcriptional profiling and chromatin immunoprecipitation coupled with massive parallel sequencing (ChIP-Seq). We found that STAT3 bound to more than 3000 genes and among its targets, we identified many genes implicated in Th17 cell differentiation (Table S1) .
As previously reported, we found that STAT3 bound to the Il17a and Il21 promoters ( Figure 4A ) (Chen et al., 2006; Nurieva et al., 2007; Wei et al., 2007) . Additionally, STAT3 bound to the Il17f promoter and the intergenic region of the Il17a and Il17f locus. In fact, intergenic STAT3 binding sites resided within conserved noncoding sequences (CNSs) and contained STAT consensus motifs ( Figure 4A and Figure S3A ). We also found STAT3 bound at multiple sites in the Il6ra gene ( Figure 4A ) and at sites in the Il23r and the Ccr6 genes (Table S1 ).
Gene expression is regulated by transcription factor binding and epigenetic modifications that control accessibility of the chromatin to transcriptional machinery (Kouzarides, 2007) . Epigenetic changes also affect cell lineage commitment and phenotypic stability by controlling transcription of essential genes . To assess the role of STAT3 in regulating epigenetic modifications, we cultured WT and (B and C) Colitis was assessed histologically at 9 weeks and severity was scored by markers of inflammation (Izcue et al., 2008 
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À/À naive T cells for 3 days under Th17 cell-polarizing conditions ( Figure S3B ) and measured histone 3 lysine 4 trimethylation (H3K4me3), a mark found at active gene loci, by ChIP-Seq ( Figure 4A and Table S1 ). We found that in WT T cells, STAT3-bound genes Il17a, Il17f, Il21, and Il6ra all contained H3K4me3 marks; however, these marks were absent or reduced in Stat3 À/À T cells. Therefore, STAT3 regulates positive epigenetic modifications of its target genes, and likely contributes to stability of the Th17 phenotype.
To assess whether STAT3 binding and H3K4me3 correlated with modulation of gene expression, we performed transcriptional profiling using microarray and quantitative PCR. Expression of IL17a, IL21, and Il6ra was markedly impaired in Stat3 À/À T cells compared to controls, particularly when the cells were differentiated with IL-6 and TGF-b ( Figure 4B ). We also found that expression of IL17f (not present on Affymetrix chips) was decreased in Stat3 À/À T cells compared to control T cells ( Figure 4C ). In contrast, expression of Ccr6 was not changed ( Figure 4B ). Thus, both STAT3 binding and increased H3K4me3 to genes were associated with STAT3-dependent expression. Th17 cell differentiation is associated with expression of several transcription factors, including RORgt, RORa, RUNX1, BATF, IRF-4, AHR, and c-Maf (Bauquet et al., 2009; Brü stle et al., 2007; Ivanov et al., 2006; Schraml et al., 2009; Veldhoen et al., 2008; Yang et al., 2008b; Zhang et al., 2008) . We assessed STAT3 binding to these transcription factor genes to determine whether it directly contributes to their regulation. RORgt, encoded by Rorc, is the master regulator of Th17 cell differentiation Immunity Defining Critical Roles of STAT3 in CD4 + T Cells and STAT3 bound to sites within the first intron ( Figure 4A ). STAT3 also bound the related retinoid receptor gene, Rora, as well as the Batf, Irf4, Ahr, and Maf genes ( Figure 4A ). We also found that STAT3 regulated permissive H3K4me3 marks on Rorc, Rora, and Batf but not on Irf4, Ahr, or Maf. This correlated well with the magnitude of their differential expression determined by microarray ( Figure 4B ). Overall, these findings support a direct function for STAT3 in regulating not only gene expression but also epigenetic modifications of key Th17 cell-related genes.
Lymphopenia-Induced Expansion of CD4 + T Cells
Requires STAT3 An important hallmark of disease in the colitis model is the accumulation of activated CD4 + T cells (Powrie et al., 1994) . As ex- This indicates that STAT3 has an important, cell-intrinsic role in driving T cell expansion in the context of inflammation and its importance is particularly evident in a competitive setting. In a chronically lymphopenic Rag2 À/À mouse, commensal bacteria and selfantigens along with cytokines drive the initial rapid expansion of naive T cells (Surh and Sprent, 2008 mice at a 1:1 ratio ( Figure 5F ). We found that the absolute number of Stat3 À/À CD4 + T cells was significantly less than wild-type T cells in the peripheral lymphoid organs and in the thymus. These findings support an essential function for STAT3 in regulating CD4 + T cell proliferation not only in pathologic settings but also during their development from precursor cells; in the T cells to accumulate under both lymphopenic and homeostatic conditions could be due to defects in proliferation, increased apoptosis, or both. To address these possibilities, we first assessed the ability of carboxyfluorescein succinimidyl ester (CFSE)-labeled naive T cells to proliferate after transfer into Rag2 À/À mice. We examined the CD4 + T cells in the spleen and found that the majority of control (Stat3 fl/fl ) T cells (86.4%) underwent multiple cell divisions after 5 days ( Figure 6A ). In contrast, fewer than half (39.2%) of Stat3 À/À T cells had divided, as indicated by CFSE dilution. By 7 days, essentially all of the control T cells had divided (98.11%), whereas 18% of Stat3 À/À T cells remained quiescent. However, by 14 days, both the Stat3 À/À and control T cells had undergone multiple rounds of division; similar levels of T cell proliferation occurred in the MLNs ( Figure S5A ). Thus, we can conclude that STAT3 influences the rate of CD4 + T cell proliferation and loss of Stat3 delays but does not abrogate T cell proliferation. As a result, fewer Stat3 À/À T cells accumulate in tissues, especially at early time points ( Figure 6B and Figure S5B ). Apoptotic cells are rapidly cleared in vivo, making it difficult to quantify cell death of adoptively transferred cells. Therefore, we further assessed cell viability in vitro by culturing naive T cells with anti-CD3 and anti-CD28 with or without STAT3-activating cytokines, IL-6 and IL-21, measuring incorporation of propidium iodide (PI) and surface expression of Annexin-V. In the absence of exogenous cytokines (medium), the proportion of apoptotic control and Stat3 À/À T cells was roughly equivalent ( Figure 6C and Figure S5C ). Addition of IL-6 or IL-21 to cultures of control T cells significantly reduced the proportion of apoptotic cells. In contrast, Stat3 À/À T cells were not responsive to IL-6 or IL-21 and had poor viability in all conditions. Activation of T cells with anti-CD3 and anti-CD28 results in endogenous IL-2 production. Consequently, addition of excess exogenous IL-2, which preferentially activates STAT5, did not enhance the viability of either the Stat3 À/À or control T cells. Taken together, these findings support the contention that STAT3 regulates T cell survival and proliferation, which in turn affect their ability to expand and elicit inflammation in a lymphopenic host.
Direct Involvement of STAT3 in Regulating Cell Survival and Proliferation Genes in CD4 + T Cells
STAT3 has been previously implicated in the regulation of genes involved in cell survival and proliferation (Bourillot et al., 2009; Hirano et al., 2000) . However, there is a paucity of data showing that STAT3 directly regulates expression of cell survival and antiapoptotic genes in CD4 + T cells. From our ChIP-Seq analysis, we found direct STAT3 binding to multiple survival genes, including Bcl2, Ier3, Fos, Jun, and Fosl2 ( Figure 7A ). Additionally, transcriptional profiling revealed that these genes were inducible in T cells by IL-6, but their induction was abrogated in Stat3 À/À T cells (Figures 7B and 7C) . We also noted that H3K4me3, permissive marks of active transcription, were present on all genes but were not absent in Stat3 À/À T cells. These findings indicate that although expression of these genes is decreased in a STAT3-dependent manner, they remain poised for transcription. This fits with our conclusion that STAT3 is important but not the only factor involved in regulating transcription of survival genes.
Taken together, the present data establish that STAT3 directly regulates genes that control survival and proliferation of CD4 + T cells. This important function of STAT3 is manifested most dramatically when T cells undergo expansion both in pathologic settings like the colitis model and in noninflammatory lymphopenic environments. However, in contrast to its roles in Th17
Immunity Defining Critical Roles of STAT3 in CD4 + T Cells cell differentiation, STAT3 is not absolutely required for T cell survival and proliferation; other factors can evidently contribute to these processes.
DISCUSSION
STAT3 has now been genetically and functionally linked to the pathogenesis of human IBD as well as other autoimmune diseases, but our understanding of STAT3's function in T cells has been surprisingly limited. Here, we have shown that Stat3 expression by T cells is essential for their colitogenic activity in a well-described model of colitis and systemic inflammation. STAT3 contributes to T cell-mediated colitis in a number of ways. First, it is essential for the differentiation of Th17 cells in vivo; in its absence T cells are nonpathogenic and tend to divert toward a Treg cell fate. Second, STAT3 mediates signals that are crucial for CD4 + T cell proliferation and survival in vivo.
Using ChIP-Seq and transcriptional profiling, we identified Figure S3 and Table  S1 . multiple genes that are direct targets of STAT3 in T cells. These included nearly all of the genes known to regulate Th17 cell differentiation as well as genes that promote survival and proliferation. Thus, STAT3 has diverse and nonredundant functions in T cells, both in pathogenic and homeostatic settings. The critical function for STAT3 in Th17 cell differentiation has been studied both in vitro and in animal models of autoimmunity. Here, we provide direct evidence that STAT3 regulates the expression of multiple genes essential for Th17 cell development. We previously showed that STAT3 binds to the Il17a promoter, but the present data show that STAT3 also binds the Il17f promoter and the intergenic region of these genes (Akimzhanov et al., 2007) . In the future it will be important to further examine how STAT3 binding to intergenic sites contributes to its regulation of Il17a and Il17f gene transcription. We also provide evidence that STAT3 controls chromatin accessibility at the Il17a, Il17f, and Il21 genes by regulating histone modifications. This adds another layer of complexity to STAT3's role as a transcriptional regulator.
Equally importantly, we have shown that STAT3 binds to and regulates the expression of several major transcription factor genes that drive Th17 cell differentiation. These include the genes encoding RORgt, RORa, BATF, IRF4, AHR, and c-Maf: factors important for promoting the program that leads to selective IL-17 production. Therefore, our findings support a broad role for STAT3 as a critical regulator of the Th17 cell transcriptional program. It will be useful to compare and contrast the array of targets for each of these transcription factors, including STAT3, to better define the hierarchy of interactions.
Previous in vitro studies have suggested that STAT3 inhibits Treg cell differentiation. In the present study, we found that STAT3 did not affect Treg cells in unperturbed mice. By contrast, STAT3 did inhibit naive T cell conversion into Foxp3-expressing cells in the context of inflammation, which is consistent with Immunity Defining Critical Roles of STAT3 in CD4 + T Cells previous work showing that both IL-6 and IL-23 inhibit regulatory T cell differentiation in autoimmune disease (Izcue et al., 2008; Korn et al., 2008) . However, it remains uncertain how this negative regulation occurs. STAT3 could regulate Foxp3 indirectly by enhancing RORgt expression, the latter being a factor that binds to and suppresses Foxp3 function. Nonetheless, Foxp3 levels are reduced in vitro by exposure to IL-6, supporting a specific inhibitory role for STAT3 in Treg cells. The mechanism underlying this effect is unclear. We also found proportionally more IFN-g + T cells in the absence of STAT3, but again, STAT3 did not bind the Ifng gene. However, these findings might be explained by reduced IL-17 production, which has recently been reported to inhibit IFN-g production in the setting of colitis (O'Connor et al., 2009).
In addition to effects on T cell differentiation, we also found that STAT3 controls T cell proliferation and survival. We were surprised by the extent to which STAT3 regulates this aspect of T cell function given that the original description of mice lacking Stat3 in T cells reported no effects on thymic or peripheral T cell development. We found that Stat3 À/À T cells exhibited reduced proliferation and failed to accumulate in the spleen or colon after transfer to Rag2 À/À mice. Strikingly, even the presence of wild-type T cells and development of severe colitis did not allow Stat3 À/À T cells to expand. These results reveal a nonredundant and cell-intrinsic requirement for STAT3 in T cell expansion during an inflammatory response. Previous reports have suggested that IL-6 is important for T cell survival in the context of inflammation (Atreya et al., 2000) . Additionally, IL-23 is (F) BM cells from wild-type (CD45.1) and Stat3 À/À mice were cotransferred into irradiated Rag2 À/À mice in a 1:1 ratio and the absolute numbers of CD4 + T cells in the tissues were calculated. *p < 0.05, **p < 0.01, ***p < 0.0005.
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Defining Critical Roles of STAT3 in CD4 + T Cells suggested to promote expansion of Th17 cells in peripheral tissues, and specifically in the colon (data not shown) (McGeachy et al., 2009) . Therefore, at least in pathologic settings, IL-6 and IL-23 are likely candidates for driving STAT3-dependent expansion of CD4 + T cells.
The requirement for STAT3 in CD4 + T cell expansion was also clearly evident in the absence of any overt inflammatory response and particularly in the setting of competitive bone marrow reconstitution. This is unexpected because IL-7 and IL-15, which predominantly activate STAT5, have been proposed to be the principal drivers of lymphopenia-induced proliferation (Surh and Sprent, 2008) . Thus, the STAT3-activating cytokine responsible for this aspect of T cell homeostasis remains to be identified.
Regardless of the cytokines responsible, it is clear from our data that STAT3 directly regulates many antiapoptotic and proproliferative genes in T cells. It has been previously suggested that Bcl-2 is activated by STAT3, but we provide the first evidence that STAT3 directly regulates Bcl2 expression. Fos and Jun dimerize to form the activator protein 1 (AP-1) transcription factor complex, which plays an important role in T cell activation. Interestingly, previous work has indicated that STAT3 cooperates with both Jun and Fos to enhance transcription of IL-6-responsive genes (Schuringa et al., 2001) . It is intriguing therefore that STAT3 can directly regulate expression of Jun and Fos and so potentially function in a positive feedback loop to regulate gene expression. It will be important to examine these pathways in more detail to gain insights into how they work together to promote T cell expansion. Equally, the finding that proliferation is not abrogated in the absence of STAT3 and that epigenetic modifications of prosurvival genes are regulated independently of STAT3 argues that this factor acts in concert with other transcription factors to regulate proliferation and cell survival.
In conclusion, our data highlight many functions of STAT3 in CD4 + T cells not previously appreciated and emphasize the pleiotropic nature of this transcription factor. In addition to multiple roles in regulating Th17 cell differentiation, STAT3 contributes to T cell homeostasis, particularly in the context of inflammation. Coupled with STAT3's known immunosuppressive function in innate and epithelial cells, our findings support a complex role for STAT3 in the immune system (Pickert et al., 2009; Takeda et al., 1999) . Given the recent genetic data implicating STAT3 in a number of human autoimmune diseases, it is clear that more careful dissection of the many functions of this key gene is warranted.
EXPERIMENTAL PROCEDURES
Mice Cd4 Cre; Stat3 fl/fl mice were generated as previously described Wei et al., 2007 
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Defining Critical Roles of STAT3 in CD4 + T Cells histologically by methods previously described (Izcue et al., 2008; Uhlig et al., 2006) . Serum was collected and protein concentrations of IL-6, IL-12p70, MCP-1, TNF-a and IL-10 were measured by cytometric bead assay (BD Biosciences).
Isolation of Leukocyte Subpopulations and Flow Cytometry
Cell suspensions were prepared from the thymus, spleen, mesenteric lymph nodes (MLNs), and colon lamina propria (LP) by methods previously described (Uhlig et al., 2006) . PerCP Cy5.5-or FITC-conjugated anti-CD4, PE-conjugated anti-TCR-b, FITC-conjugated anti-CD45.1, and APC-conjugated anti-CD8 were from BD Biosciences. PE or FITC anti-Foxp3 staining set was from eBioscience. For intracellular cytokine staining, cells were cultured for 4 hr with PMA (50 ng/ml), ionomycin (1 mg/ml) and BFA (GolgiPlug; BD Biosciences), stained for CD4, fixed, and permeabilized in buffers from BD Biosciences. Cells were stained with PE or APC anti-IFN-g, PE anti-IL-17A (all from BD Biosciences) or Alexa Fluor-647 anti-IL-17A (eBioscience), or appropriate isotype controls (BD Biosciences). For in vitro activation, naive T cells were cultured for 3 days with 5 mg/ml each of platebound anti-CD3 and anti-CD28 (BD Biosciences) alone or with 100 U/ml IL-2 (Peprotech), 10 ng/ml IL-6 (eBioscience) and 10 ng/ml IL-21(R&D). FITC or APC anti-Annexin-V antibody and propidium iodide (BD Biosciences) were used for apoptosis assessment. Cells were acquired on the FACSCaliber (BD Biosciences) and analyzed with FlowJo 8.7.3 software (Tree Star). T cells were isolated and sorted on the FACSAria flow cytometer. Cells were cultured for 72 hr with CD3 (5 mg/ml) and CD28 (5 mg/ml), IL-6 (10 ng/ml), and TGF-b (2.5 ng/ml) with blocking antibodies to 10 mg/ml IL-2, 10 mg/ml IL-4, and 10 mg/ml IFN-g. Cells were restimulated for 1 hr with IL-6 (10 ng/ml) and then processed for ChIP-Seq as previously described (Wei et al., 2009) . Antibodies against histone H3K4me3 (ab8580, Abcam) and phosphoserine (PS)-STAT3 (Cat. #9134, Cell Signaling) were used. The ChIP DNA fragments were blunt-ended, ligated to the illumina adaptors, and sequenced with the Illumina Genome Analyzer II. Details of how the level of STAT3 binding and histone modifications were calculated for all genes can be found in Table S1 .
Homeostatic Proliferation and Stem Cell
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For microarray analysis, control or Stat3 À/À naive T cells were activated for 3 days with anti-CD3, anti-CD28 alone, or with IL-6 (10 ng/ml) and TGFb (2.5 ng/ml). RNA was purified (MirVana miRNA isolation kit, Ambion), reverse transcribed, and biotinylated (MessageAmp II-Biotin Enhanced Kit, Ambion). Labeled aRNA (10 mg) was hybridized to GeneChip Mouse Genome 430 2.0 arrays (Affimetrix) in accordance with the manufacturer's protocols. Expression was determined with GeneChip Operating Software (GCOS; v1.1.1) and analysis was performed with GeneSpring software GX 10.0.1 (Agilent Technologies). For quantitative PCR, RNA was purified as above and reverse transcribed (Applied Biosystems). Taqman Master Mix and primers from Applied Biosystems were used for qPCR reactions. Each assay was performed in triplicate with an ABI Fast detection system and gene expression levels were normalized to 18 s rRNA and internal controls (medium alone) with DDCt calculations.
Statistics GraphPad Prism 4.0 was used for statistical analysis (unpaired, two-tailed, t test with a confidence interval of 95%). Differences were considered statistically significant when p < 0.05.
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